Caredx Inc Dossier
Qualitative Analysis
Business overview
CareDx, Inc. (Nasdaq: CDNA) is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Headquartered in Brisbane, California, the company provides genomics-based information and non-invasive molecular testing services across the pre- and post-transplant patient journey. Its core commercialized testing services include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. CareDx also offers patient and digital solutions, such as Ottr transplant patient management software, and has historically provided laboratory products for HLA typing.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding CareDx's precision medicine capabilities from solid organ transplantation into cell therapy, hematology, and oncology. This includes advancing the AlloHeme pipeline program for surveillance of relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Expected impact: Expands the company's total addressable market (TAM) and establishes a leading position in cellular-resolution post-transplant monitoring.
Integrating CareDx's testing solutions directly into clinical workflows via Epic Electronic Medical Record (EMR) systems. This includes launching AlloSure Plus, an AI-enabled risk assessment solution for kidney transplant surveillance, through Epic integration.
Expected impact: Improves operational efficiency, reduces claim submission errors, and drives higher testing volume adherence through seamless clinical workflow integration.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Extends CareDx's strategy into specialty oncology with a Medicare-reimbursed, commercial-stage molecular residual disease (MRD) test (NavDx) and platform for viral-mediated cancers, addressing a $4.5 billion TAM.
Financial impact: Naveris generated $34 million in 2025 revenue (expected to grow 30-40% annually). The transaction is expected to be neutral to CareDx's FY2026 Adjusted EBITDA guidance.
Strategic Partnerships
Establishing ImmuneScape, a multiomics research initiative designed to elucidate the biology of transplant organ rejection (antibody-mediated rejection and microvascular inflammation) and therapeutic response. CareDx will leverage 10x Genomics' Xenium spatial and Chromium Flex single-cell platforms to support future clinical diagnostic pipeline development.
Terms: Terms not publicly disclosed.